NO TUITION FEE for Pre-Clinical(MD/MS)/Para Clinical(MD) courses except for MD Pathology course for the A.Y.2024-25                 Hall tickets to be issued for MBBS Phase-I and Phase -II December 2024 examination.                

Projects Current & Completed

Projects Current & Completed

Ongoing clinical trials
  1. Phase-I studies- A Phase 1, Open Label, Dose Escalation, Dose Expansion, Multicentre, First in Human (FIH) Study Evaluating the Safety, Pharmacokinetics and Pharmacodynamics of Oral AUR107 in Patients with Relapsed Advanced Malignancies. Principal investigators-Dr.Shashidhar.V.K, Co-Investigators-Dr.Manjunath.N, Dr.Veerendra Angadi
  2.  Phase1, Open Label First in Human Study Investigating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of HPK1 Inhibitor GRC 54276 Alone and in Combination with Anti-PD-1 Monoclonal Antibody Pembrolizumab or Anti-PD-L1 Atezolizumab in Subjects with Advanced Solid Tumors and Lymphomas. Principal Investigator- Dr.Manjunath.I.N, CO-Investigators-Dr.Shashidhar.v.Karpurmath, Dr.Veerendra Angadi
  3. NAGA trial: A phase III, multi centre RCT –Neoadjuvant vs adjuvant chemotherapy in gastric Adeno carcinoma. Principal investigators-Dr. Shashidhar. V.K, Co-Investigators-Dr. Manjunath. N, Dr. Veerendra Angadi
Completed clinical trials
Indication of trial Phase of  Trial Role In Trial Year
A phase IIb/III,Randomised, Double-blind, Placebo-Controlled, Multicentre, Study of CA-170 in combination with Chemotherapy in patients with Stage IV Non-Squamous Non-Small Cell lung Cancer. Phase III Principal Investigator 2023
An open label, Multi-Centre, Randomized, Two-Treatment, and Multi dose, parallel, Comparative Bioavailability Study of Bertezomib Injection 3.5mg/0.2ml and VECADE 3.5mg powder for solution for injection at a dose of .3mg/m2 in Multiple Myeloma Patients. Phase-III Co- Investigator 2021
A multi-centre, Double-Blind, randomized parallel Group, Active controlled, Two Part, Phase-III, Global Study to Evaluate the Pharmacokinetics, Effiacy,and Safety of BP 02 (Trastuzumab) in Comparison with Herceptin- EU in patients with Her2-positive Early Breast Cancer and Metastatic Breast Cancer. Phase-III Co- Investigator 2019-2022
Prospective , multi-center, randomized,double-blind,two-arm,parallel group, active control, comparative clinical study to evaluate efficacy and safety of R-TPR_045/Xgeva for prevention of skeletal related events in patients with bone metastases from solid tumours. Phase-III Co- Investigator 2018-2019
Metastatic Breast Cancer Phase-III Principal Investigator 2017-2018
A prospective , Multicenter, randomize, double blind, phase III study to compare the efficacy and safety of Biosimilar Bevacizumab of Enzene Biosciences LTD versus Innovator Bevacizumab both in combination with CAPEOX in Patients with Metastatic Colorectal Cancer Phase-III Principal Investigator 2016-2017
A randomized open label single dose two treatment three sequence partial replicate cross over multicenter bioequivalence study of Capecitabine 500 mg tablets with Xeloda in adult cancer patients under fed conditions- Completed US FDA inspection for the same. Phase-III Principal Investigator 2018-2019
ICMR Project study
  • To validate the utility of Chemotherapy Risk Assessment Scale for High Age patients (CRASH score) in predicting chemotherapy toxicity in elderly cancer patients.
    Research proposal accepted by ICMR under STS (Short term Studentship) for the year 2020.